Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AscoPharm is conducting the study under the responsibility of SEPTODONT | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
TRIAL TITLE Open trial, not randomized study evaluating the efficacy and the tolerance of RD94 in patients needing endodontic care, medical device class III.
SPONSOR:
SEPTODONT, 58 rue de Pont de Créteil, 94107 Saint Maur des Fossés cedex Tel : + 33 1-49-76-74-26, Fax. : + 33 1- 49-76-71-91
Reference protocol: 09/001
PRODUCT NAME: Biodentine™ (RD94)
MEDICAL DEVICE:
Class: Bioactive dental substitute (Tricalcium silicate) Dose: not applicable Application : one single time
DEVELOPMENTAL PHASE: not applicable (medical device class III)
METHODOLOGY:
This multi-centre and open-label study comprises six groups corresponding to the six indications tested. No placebo or reference product is involved. No randomization is required as the indication will define the patient selection.
The six indications studied are:
Study start: October 2009
Inclusion period: 1/10/2009 to 30/06/2011
Study duration: 2 years
OBJECTIVES:
The trial objective is to illustrate the clinical efficacy and tolerance of RD94 in the indications described.
Primary objective:
The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 6 month follow-up.
Secondary objective:
The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product.
TRIAL POPULATION AND NUMBER OF PATIENTS:
60 patients in three French study centers, 10 per indication studied. Depending on the indication, children (from 3 years onwards), and/or adults will be included.
DURATION OF TREATMENT:
The product is applied on D0 (Inclusion) of the study. The follow-up period includes 2 years with six visits: Visit1 - Week 1, Visit 2 - Month 1, Visit 3 - Month 3, Visit 4 - Month 6, Visit 5 - Year 1, Visit 6 - Year 2.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Direct pulp capping/carious exposure | Experimental | symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation. |
|
| Direct pulp capping/dental trauma | Experimental | • Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure. |
|
| Repairing root canals/pulp chamber floor | Experimental |
|
|
| Retrograde endodontic surgery - adults | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Application of Biodentine™ (RD94), dentin substitute | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy | The primary objective is to show that RD94 can be easily applied in the claimed indications and to evaluate its efficacy. This can be defined after a 3 month follow-up. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Long term efficacy and safety | The secondary objective is to evaluate the efficacy of RD94 after a two year follow-up which is important for safety and the longevity of the product. | 2 years |
Not provided
Inclusion Criteria
Direct pulp capping following dental trauma injury to healthy pulp, reformulated as a partial pulpotomy - children (6 to 18 years) + adults
- Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
Repairing perforated root canals and/or the pulp chamber floor - adults
Retrograde endodontic surgery - adults
Pulpotomy in primary molars - children ( 3 to 12 years )
Apexification - children (7 to 18 years) + adults
Exclusion Criteria
3 Risk A cardiopathies 4. Known hypersensitivity to one of the components of the study or procedural medications.
5. Presence or history of severe systemic allergy. 6. Presence or history of drug addiction or alcohol abuse. 7. Patient who has participated in a clinical trial with a new active substance during the month before study entry.
8. Participation in another clinical study at the same time as the present study.
9. Known pregnancy or lactation at study entry.
exclusion criteria for each indication : Direct pulp capping following carious pulp exposure
Repairing perforated root canals and/or the pulp chamber floor
Pulpotomy:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frédéric RILLIARD, Pr | Université Paris 7-Denis Diderot | Principal Investigator |
| Chantal Naulin-Ifi, Docteur | Service d'Odontologie du GHPS | Principal Investigator |
| Pierre Colon, Pr | Université Paris VII Garancière. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cabinet de Chirurgie Dentaire rue Saint Didier | Paris | France | ||||
| Service d'endodontie de la Pitié Salpêtrière Hôpital de la Pitié Salpêtrière |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 17, 2015 | |
| Reset | Mar 25, 2015 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 17, 2015 | Mar 25, 2015 |
| ID | Term |
|---|---|
| D018677 | Tooth Injuries |
| ID | Term |
|---|---|
| D014076 | Tooth Diseases |
| D009057 | Stomatognathic Diseases |
| D014947 | Wounds and Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Pulpotomy in primary molars - children (3 to 12 years ) | Experimental |
|
|
| Apexification - children (7 to 18 years) + adults | Experimental |
|
|
| Paris |
| France |
| Service d'Odontologie Hôpital Rothschild | Paris | France |